ID
33909
Description
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION); ODM derived from: https://clinicaltrials.gov/show/NCT01818752
Link
https://clinicaltrials.gov/show/NCT01818752
Keywords
Versions (1)
- 1/7/19 1/7/19 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
January 7, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Multiple Myeloma NCT01818752
Eligibility Multiple Myeloma NCT01818752
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Waldenstrom Macroglobulinemia
Data type
boolean
Alias
- UMLS CUI [1]
- C0024419
Description
Amyloidosis
Data type
boolean
Alias
- UMLS CUI [1]
- C0002726
Description
Leukemia, Plasma Cell
Data type
boolean
Alias
- UMLS CUI [1]
- C0023484
Description
POEMS Syndrome
Data type
boolean
Alias
- UMLS CUI [1]
- C0085404
Description
Neuropathy CTCAE Grades
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0442874
- UMLS CUI [1,2]
- C1516728
Similar models
Eligibility Multiple Myeloma NCT01818752
- StudyEvent: Eligibility
C0231220 (UMLS CUI [1,2])
C0040732 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,2])